查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1552541

監管事務市場規模、佔有率、趨勢分析報告：按類別、公司規模、類型、服務、產品階段、適應症、最終用途、地區、細分市場預測，2024-2030 年

Regulatory Affairs Market Size, Share & Trends Analysis Report By Categories (Drugs, Biologics), By Company Size (Small, Large), By Type, By Services, By Product Stage, By Indication, By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

監管事務市場成長和趨勢

Grand View Research, Inc.的最新報告顯示，2024年至2030年，全球監管事務市場預計將以8.2%的複合年成長率成長，到2030年將達到260億美元。

預計有助於市場成長的因素包括業務活動和地區不斷變化的監管要求、由於監管核准速度加快而導致的臨床試驗和藥物核准的增加，以及監管軟體的技術進步。個人化藥物的發展、公司越來越需要專注於其核心業務活動以及經濟和競爭市場壓力也是市場成長的因素。

製藥公司和監管機構已聯手快速開發對抗 COVID-19 感染所需的疫苗和醫療產品。監管機構已採取多種預防措施，以確保臨床試驗期間患者和人員的安全，並確保資料和良好的實驗室業務得以維持。生物相似藥、孤兒藥、個人化藥物、伴同性診斷和適應性試驗設計等市場的成長預計將推動這些領域對監管專業知識的需求。隨著公司擴展到新的細分市場，遵守法規的需求不斷增加，對具有業務專業知識的專業服務供應商的需求也在增加。由於 Simrect、 Vectibix、 Mircera和 Kineret 等生技藥品的專利到期，生物相似藥的需求和開發不斷增加，從而增加了對監管服務的需求。

公司正在積極合作並開拓新產品，以獲得個人化醫療市場的主導，這表明需要業務支持。例如，2020 年 5 月，Regeneron Pharmaceuticals, Inc. 與科羅拉多州個人化醫療中心合作，推動個人化醫療和人類遺傳學的進步。

監理事務市場報告亮點

  • 2023年，外包產業以58.16%的佔有率佔據市場主導地位。此細分市場的成長主要歸功於製藥和醫療設備公司對外包的關注，這使他們能夠獲得內部不具備的專業知識和資源。
  • 監管寫作和出版領域佔據市場主導地位，2023 年佔全球銷售額的 36.41%。
  • 醫療設備領域在2023年佔據市場主導地位，佔有率為41.05%。該細分市場的成長得益於技術的不斷進步以及越來越多的參與企業市場專注於外包醫療設備業務，以便他們能夠更加專注於自己的核心競爭力等因素。
  • 腫瘤學領域在2023年佔據市場主導地位，佔有率為32.77%。該細分市場的成長主要是由於癌症盛行率的增加，這需要有效和安全的治療方案。
  • 亞太地區佔據市場主導地位，2023年佔37.82%的佔有率。該地區的成長得益於更強力的監管環境、臨床試驗的增加、製藥公司數量的增加以及該地區技術純熟勞工的供應等因素。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章 監理事務市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/補充市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 監理事務市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章 監理事務市場：服務、估算與趨勢分析

  • 細分儀表板
  • 全球監管事務市場服務波動分析
  • 2018-2030 年全球監理事務市場規模與趨勢分析（按服務）
  • 監理諮詢
  • 法律代表
  • 撰寫和發布規範文件
  • 產品註冊及臨床試驗申請
  • 其他

第5章 監理事務市場：類別、估算與趨勢分析

  • 細分儀表板
  • 全球監理事務市場品類變化分析
  • 2018-2030年全球監理事務市場規模及趨勢分析（依類別）
  • 藥品
  • 生技藥品
  • 醫療設備

第6章 監理事務市場：指標、估計與趨勢分析

  • 細分儀表板
  • 全球監管事務市場指標波動分析
  • 2018-2030 年全球監理事務市場規模與趨勢分析（依指標）
  • 腫瘤學
  • 神經病學
  • 心臟病學
  • 免疫學
  • 其他

第7章 監理事務市場：產品階段、估算與趨勢分析

  • 細分儀表板
  • 全球監理事務市場產品階段變化分析
  • 2018-2030年全球監理事務市場規模及趨勢分析（依產品階段）
  • 臨床前
  • 臨床研究
  • PMA

第8章監理事務市場：類型、估計與趨勢分析

  • 細分儀表板
  • 全球監管事務市場類型波動分析
  • 2018-2030 年全球監理事務市場規模及趨勢分析（按類型）
  • 公司內部
  • 外包

第9章 監理事務市場：公司規模、估算及趨勢分析

  • 細分儀表板
  • 全球監理事務市場公司規模變化分析
  • 2018-2030 年全球監理事務市場規模及趨勢分析（依公司規模）
  • 小的
  • 中等的
  • 大的

第10章監理事務市場：最終用途、估計與趨勢分析

  • 細分儀表板
  • 全球監管事務市場的最終用途變化分析
  • 2018-2030 年全球監理事務市場規模與趨勢分析（依最終用途）
  • 醫療設備公司
  • 製藥公司
  • 生技公司

第11章 監理事務市場：按地區估算及趨勢分析

  • 2023 年及 2030 年按地區分類的市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 2018-2030年北美市場估算與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018-2030 年歐洲市場估計與預測
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 挪威
    • 荷蘭
    • 瑞士
    • 瑞典
  • 亞太地區
    • 2018-2030 年亞太市場估計與預測
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
    • 印尼
    • 馬來西亞
    • 新加坡
    • 台灣
  • 拉丁美洲
    • 2018-2030 年拉丁美洲市場估計與預測
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
  • 中東/非洲
    • 2018-2030 年中東和非洲市場估計和預測
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 埃及
    • 以色列
    • 科威特

第12章競爭格局

  • 公司/競爭對手分類
  • 策略規劃
  • 2023 年企業市場分析
  • 公司簡介/上市公司
    • Accell Clinical Research, LLC
    • Genpact
    • Criterium, Inc.
    • ICON plc
    • iuvo BioScience, llc.
    • WuXi AppTec
    • Medpace
    • Charles River Laboratories
    • Laboratory Corporation of America Holdings
    • Parexel International（MA）Corporation
    • Freyr
    • PHARMALEX GMBH
    • SSI Strategy LLC
    • Pharmexon
    • Qvigilance
    • BlueReg
    • Cambridge Regulatory Services
    • VCLS
Product Code: GVR-4-68039-065-9

Regulatory Affairs Market Growth & Trends:

The global regulatory affairs market size is expected to reach USD 26.0 billion by 2030, expanding at a CAGR of 8.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The factors expected to contribute to the growth of this market include changing regulatory requirements based on business activities and geographies, an increase in clinical trials & drug approvals along with accelerated regulatory approval, and technological advancement in regulatory software. Also, the evolution of personalized medicines, the increasing need for companies to focus on core business activities, and economic and competitive pressures are other factors that are contributing to the growth of the market.

The pharmaceutical and regulatory agencies joined forces to rapidly develop vaccines and medical products required to fight against the COVID-19 infection. The regulatory authorities take numerous precautions to ensure patient and personnel safety during a clinical trial, as well as data integrity and good laboratory practices are maintained. Growth in markets for biosimilars, orphan drugs, personalized medicines, companion diagnostics, and adaptive trial designs is projected to boost the demand for regulatory specialization in these areas. As companies venture into newer fields, the growing need to comply with regulations is boosting the demand for specialized service providers with expertise in regulatory affairs. Patent expiration of biologics, such as Simulect, Vectibix, Mircera, and Kineret, is increasing the demand and development of biosimilars, thereby contributing to the demand for regulatory services.

Several companies are actively involved in collaborations and new product development to gain leadership in the personalized medicine market, indicating a need for supportive regulatory affairs. For instance, in May 2020, Regeneron Pharmaceuticals, Inc. collaborated with Colorado Center for Personalized Medicine to design advancements in personalized medicine and human genetics.

Regulatory Affairs Market Report Highlights:

  • The outsourcing segment dominated the market with a share of 58.16% in 2023. The segment's growth is mainly due to the growing focus of pharmaceutical and medical device companies on outsourcing their activities, which allows them to access specialized expertise and resources they may not have in-house.
  • The regulatory writing & publishing segment dominated the market, accounting for 36.41% of the global revenue in 2023.
  • The medical devices segment dominated the market with a share of 41.05% in 2023. The segment's growth can be attributed to factors such as constant technological advancements and the increasing focus of market players on outsourcing medical device activities so they can focus more on their core competencies.
  • The oncology segment dominated the market with a share of 32.77% in 2023. The growth of the segment is mainly due to the increasing prevalence of cancer, which requires effective and safe treatment options.
  • Asia Pacific dominated the market and accounted for a 37.82% share in 2023. The growth in the region is attributed to factors such as an enhanced regulatory landscape, an increasing number of clinical trials, a growing number of pharmaceutical companies, and the availability of skilled workers in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Type Segment
    • 1.2.2. Services Segment
    • 1.2.3. Category Segment
    • 1.2.4. Indication Segment
    • 1.2.5. Product Stage Segment
    • 1.2.6. Company Size Segment
    • 1.2.7. Indication Segment
    • 1.2.8. End Use Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. Regulatory Affairs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Changing Regulatory Landscape
      • 3.2.1.2. Entry Of Companies into The Global Market
      • 3.2.1.3. Life Science Companies Focusing on Their Core Competencies
      • 3.2.1.4. Economic And Competitive Pressures
      • 3.2.1.5. Demand For the Faster Approval Process for Breakthrough Drugs and Devices
      • 3.2.1.6. Growth In Emerging Areas Such as Personalized Medicine, Biosimilars, And Orphan Drugs
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Risk Associated with Data Security
      • 3.2.2.2. Monitoring Issues and Lack of Standardization
  • 3.3. Regulatory Affairs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Regulatory Affairs Market: Services Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Regulatory Affairs Market Services Movement Analysis
  • 4.3. Global Regulatory Affairs Market Size & Trend Analysis, by Services, 2018 to 2030 (USD Billion)
  • 4.4. Regulatory Consulting
    • 4.4.1. Regulatory consulting market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 4.5. Legal Representation
    • 4.5.1. Legal representation market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 4.6. Regulatory Writing & Publishing
    • 4.6.1. Regulatory writing & publishing market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 4.6.2. Writing
      • 4.6.2.1. Writing market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 4.6.3. Publishing
      • 4.6.3.1. Publishing market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 4.7. Product Registration & Clinical Trial Applications
    • 4.7.1. Product registration & clinical trial applications market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 4.8. Other Services
    • 4.8.1. Other services market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Regulatory Affairs Market: Category Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Regulatory Affairs Market Category Movement Analysis
  • 5.3. Global Regulatory Affairs Market Size & Trend Analysis, by Category, 2018 to 2030 (USD Billion)
  • 5.4. Drugs
    • 5.4.1. Drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.4.2. Innovator
      • 5.4.2.1. Innovator market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.4.2.2. Preclinical
        • 5.4.2.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.4.2.3. Clinical
        • 5.4.2.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.4.2.4. Pre-Market Approval (PMA)
        • 5.4.2.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.4.3. Generics
      • 5.4.3.1. Generics market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.4.3.2. Preclinical
        • 5.4.3.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.4.3.3. Clinical
        • 5.4.3.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.4.3.4. Pre-Market Approval (PMA)
        • 5.4.3.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.5. Biologics
    • 5.5.1. Biologics market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.5.2. Biotech
      • 5.5.2.1. Biotech market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.5.2.2. Preclinical
        • 5.5.2.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.5.2.3. Clinical
        • 5.5.2.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.5.2.4. Pre-Market Approval (PMA)
        • 5.5.2.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.5.3. ATMP
      • 5.5.3.1. ATMP market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.5.3.2. Preclinical
        • 5.5.3.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.5.3.3. Clinical
        • 5.5.3.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.5.3.4. Pre-Market Approval (PMA)
        • 5.5.3.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.5.4. Biosimilars
      • 5.5.4.1. Biosimilars market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.5.4.2. Preclinical
        • 5.5.4.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.5.4.3. Clinical
        • 5.5.4.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.5.4.4. Pre-Market Approval (PMA)
        • 5.5.4.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.6. Medical Devices
    • 5.6.1. Medical devices market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.6.2. Diagnostics
      • 5.6.2.1. Diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.6.2.2. Preclinical
        • 5.6.2.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.6.2.3. Clinical
        • 5.6.2.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.6.2.4. Pre-Market Approval (PMA)
        • 5.6.2.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.6.3. Therapeutics
      • 5.6.3.1. Therapeutics market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.6.3.2. Preclinical
        • 5.6.3.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.6.3.3. Clinical
        • 5.6.3.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.6.3.4. Pre-Market Approval (PMA)
        • 5.6.3.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Regulatory Affairs Market: Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Regulatory Affairs Market Indication Movement Analysis
  • 6.3. Global Regulatory Affairs Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Billion)
  • 6.4. Oncology
    • 6.4.1. Oncology market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 6.5. Neurology
    • 6.5.1. Neurology market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 6.6. Cardiology
    • 6.6.1. Cardiology market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 6.7. Immunology
    • 6.7.1. Immunology market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 6.8. Others
    • 6.8.1. Others market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Regulatory Affairs Market: Product Stage Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Regulatory Affairs Market Product Stage Movement Analysis
  • 7.3. Global Regulatory Affairs Market Size & Trend Analysis, by Product Stage, 2018 to 2030 (USD Billion)
  • 7.4. Preclinical
    • 7.4.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Clinical studies
    • 7.5.1. Clinical studies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 7.6. PMA
    • 7.6.1. PMA market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Regulatory Affairs Market: Type Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Global Regulatory Affairs Market Type Movement Analysis
  • 8.3. Global Regulatory Affairs Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Billion)
  • 8.4. In-house
    • 8.4.1. In-house market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 8.5. Outsourced
    • 8.5.1. Outsourced market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 9. Regulatory Affairs Market: Company Size Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Global Regulatory Affairs Market Company Size Movement Analysis
  • 9.3. Global Regulatory Affairs Market Size & Trend Analysis, by Company Size, 2018 to 2030 (USD Billion)
  • 9.4. Small
    • 9.4.1. Small market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 9.5. Medium
    • 9.5.1. Medium market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 9.6. Large
    • 9.6.1. Large market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 10. Regulatory Affairs Market: End Use Estimates & Trend Analysis

  • 10.1. Segment Dashboard
  • 10.2. Global Regulatory Affairs Market End Use Movement Analysis
  • 10.3. Global Regulatory Affairs Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Billion)
  • 10.4. Medical Device Companies
    • 10.4.1. Medical device companies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 10.5. Pharmaceutical Companies
    • 10.5.1. Pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 10.6. Biotechnology Companies
    • 10.6.1. Biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 11. Regulatory Affairs Market: Regional Estimates & Trend Analysis

  • 11.1. Regional Market Share Analysis, 2023 & 2030
  • 11.2. Regional Market Dashboard
  • 11.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 11.4. North America
    • 11.4.1. North America Market Estimates and Forecasts 2018 - 2030 (USD Billion)
    • 11.4.2. U.S.
      • 11.4.2.1. Key country dynamics
      • 11.4.2.2. Competitive scenario
      • 11.4.2.3. U.S. market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.4.3. Canada
      • 11.4.3.1. Key country dynamics
      • 11.4.3.2. Competitive scenario
      • 11.4.3.3. Canada market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.4.4. Mexico
      • 11.4.4.1. Key country dynamics
      • 11.4.4.2. Competitive scenario
      • 11.4.4.3. Mexico market estimates and forecasts 2018 - 2030 (USD Billion)
  • 11.5. Europe
    • 11.5.1. Europe Market Estimates and Forecasts 2018 - 2030 (USD Billion)
    • 11.5.2. UK
      • 11.5.2.1. Key country dynamics
      • 11.5.2.2. Competitive scenario
      • 11.5.2.3. UK market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.5.3. Germany
      • 11.5.3.1. Key country dynamics
      • 11.5.3.2. Competitive scenario
      • 11.5.3.3. Germany market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.5.4. France
      • 11.5.4.1. Key country dynamics
      • 11.5.4.2. Competitive scenario
      • 11.5.4.3. France market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.5.5. Italy
      • 11.5.5.1. Key country dynamics
      • 11.5.5.2. Competitive scenario
      • 11.5.5.3. Italy market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.5.6. Spain
      • 11.5.6.1. Key country dynamics
      • 11.5.6.2. Competitive scenario
      • 11.5.6.3. Spain market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.5.7. Denmark
      • 11.5.7.1. Key country dynamics
      • 11.5.7.2. Competitive scenario
      • 11.5.7.3. Denmark market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.5.8. Norway
      • 11.5.8.1. Key country dynamics
      • 11.5.8.2. Competitive scenario
      • 11.5.8.3. Norway market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.5.9. Netherlands
      • 11.5.9.1. Key country dynamics
      • 11.5.9.2. Competitive scenario
      • 11.5.9.3. Netherlands market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.5.10. Switzerland
      • 11.5.10.1. Key country dynamics
      • 11.5.10.2. Competitive scenario
      • 11.5.10.3. Switzerland market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.5.11. Sweden
      • 11.5.11.1. Key country dynamics
      • 11.5.11.2. Competitive scenario
      • 11.5.11.3. Sweden market estimates and forecasts 2018 - 2030 (USD Billion)
  • 11.6. Asia Pacific
    • 11.6.1. Asia Pacific Market Estimates and Forecasts 2018 - 2030 (USD Billion)
    • 11.6.2. Japan
      • 11.6.2.1. Key country dynamics
      • 11.6.2.2. Competitive scenario
      • 11.6.2.3. Japan market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.6.3. China
      • 11.6.3.1. Key country dynamics
      • 11.6.3.2. Competitive scenario
      • 11.6.3.3. China market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.6.4. India
      • 11.6.4.1. Key country dynamics
      • 11.6.4.2. Competitive scenario
      • 11.6.4.3. India market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.6.5. Australia
      • 11.6.5.1. Key country dynamics
      • 11.6.5.2. Competitive scenario
      • 11.6.5.3. Australia market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.6.6. South Korea
      • 11.6.6.1. Key country dynamics
      • 11.6.6.2. Competitive scenario
      • 11.6.6.3. South Korea market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.6.7. Thailand
      • 11.6.7.1. Key country dynamics
      • 11.6.7.2. Competitive scenario
      • 11.6.7.3. Thailand market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.6.8. Indonesia
      • 11.6.8.1. Key country dynamics
      • 11.6.8.2. Competitive scenario
      • 11.6.8.3. Indonesia market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.6.9. Malaysia
      • 11.6.9.1. Key country dynamics
      • 11.6.9.2. Competitive scenario
      • 11.6.9.3. Malaysia market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.6.10. Singapore
      • 11.6.10.1. Key country dynamics
      • 11.6.10.2. Competitive scenario
      • 11.6.10.3. Singapore market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.6.11. Taiwan
      • 11.6.11.1. Key country dynamics
      • 11.6.11.2. Competitive scenario
      • 11.6.11.3. Taiwan market estimates and forecasts 2018 - 2030 (USD Billion)
  • 11.7. Latin America
    • 11.7.1. Latin America Market Estimates and Forecasts 2018 - 2030 (USD Billion)
    • 11.7.2. Brazil
      • 11.7.2.1. Key country dynamics
      • 11.7.2.2. Competitive scenario
      • 11.7.2.3. Brazil market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.7.3. Argentina
      • 11.7.3.1. Key country dynamics
      • 11.7.3.2. Competitive scenario
      • 11.7.3.3. Argentina market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.7.4. Colombia
      • 11.7.4.1. Key country dynamics
      • 11.7.4.2. Competitive scenario
      • 11.7.4.3. Colombia market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.7.5. Chile
      • 11.7.5.1. Key country dynamics
      • 11.7.5.2. Competitive scenario
      • 11.7.5.3. Chile market estimates and forecasts 2018 - 2030 (USD Billion)
  • 11.8. MEA
    • 11.8.1. MEA Market Estimates and Forecasts 2018 - 2030 (USD Billion)
    • 11.8.2. South Africa
      • 11.8.2.1. Key country dynamics
      • 11.8.2.2. Competitive scenario
      • 11.8.2.3. South Africa market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.8.3. Saudi Arabia
      • 11.8.3.1. Key country dynamics
      • 11.8.3.2. Competitive scenario
      • 11.8.3.3. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.8.4. UAE
      • 11.8.4.1. Key country dynamics
      • 11.8.4.2. Competitive scenario
      • 11.8.4.3. UAE market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.8.5. Egypt
      • 11.8.5.1. Key country dynamics
      • 11.8.5.2. Competitive scenario
      • 11.8.5.3. Egypt market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.8.6. Israel
      • 11.8.6.1. Key country dynamics
      • 11.8.6.2. Competitive scenario
      • 11.8.6.3. Israel market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.8.7. Kuwait
      • 11.8.7.1. Key country dynamics
      • 11.8.7.2. Competitive scenario
      • 11.8.7.3. Israel market estimates and forecasts 2018 - 2030 (USD Billion)

Chapter 12. Competitive Landscape

  • 12.1. Company/Competition Categorization
  • 12.2. Strategy Mapping
  • 12.3. Company Market Position Analysis, 2023
  • 12.4. Company Profiles/Listing
    • 12.4.1. Accell Clinical Research, LLC
      • 12.4.1.1. Company overview
      • 12.4.1.2. Financial performance
      • 12.4.1.3. Product benchmarking
      • 12.4.1.4. Strategic initiatives
    • 12.4.2. Genpact
      • 12.4.2.1. Company overview
      • 12.4.2.2. Financial performance
      • 12.4.2.3. Product benchmarking
      • 12.4.2.4. Strategic initiatives
    • 12.4.3. Criterium, Inc.
      • 12.4.3.1. Company overview
      • 12.4.3.2. Financial performance
      • 12.4.3.3. Product benchmarking
      • 12.4.3.4. Strategic initiatives
    • 12.4.4. ICON plc
      • 12.4.4.1. Company overview
      • 12.4.4.2. Financial performance
      • 12.4.4.3. Product benchmarking
      • 12.4.4.4. Strategic initiatives
    • 12.4.5. iuvo BioScience, llc.
      • 12.4.5.1. Company overview
      • 12.4.5.2. Financial performance
      • 12.4.5.3. Product benchmarking
      • 12.4.5.4. Strategic initiatives
    • 12.4.6. WuXi AppTec
      • 12.4.6.1. Company overview
      • 12.4.6.2. Financial performance
      • 12.4.6.3. Product benchmarking
      • 12.4.6.4. Strategic initiatives
    • 12.4.7. Medpace
      • 12.4.7.1. Company overview
      • 12.4.7.2. Financial performance
      • 12.4.7.3. Product benchmarking
      • 12.4.7.4. Strategic initiatives
    • 12.4.8. Charles River Laboratories
      • 12.4.8.1. Company overview
      • 12.4.8.2. Financial performance
      • 12.4.8.3. Product benchmarking
      • 12.4.8.4. Strategic initiatives
    • 12.4.9. Laboratory Corporation of America Holdings
      • 12.4.9.1. Company overview
      • 12.4.9.2. Financial performance
      • 12.4.9.3. Product benchmarking
      • 12.4.9.4. Strategic initiatives
    • 12.4.10. Parexel International (MA) Corporation
      • 12.4.10.1. Company overview
      • 12.4.10.2. Financial performance
      • 12.4.10.3. Product benchmarking
      • 12.4.10.4. Strategic initiatives
    • 12.4.11. Freyr
      • 12.4.11.1. Company overview
      • 12.4.11.2. Financial performance
      • 12.4.11.3. Product benchmarking
      • 12.4.11.4. Strategic initiatives
    • 12.4.12. PHARMALEX GMBH
      • 12.4.12.1. Company overview
      • 12.4.12.2. Financial performance
      • 12.4.12.3. Product benchmarking
      • 12.4.12.4. Strategic initiatives
    • 12.4.13. SSI Strategy LLC
      • 12.4.13.1. Company overview
      • 12.4.13.2. Financial performance
      • 12.4.13.3. Product benchmarking
      • 12.4.13.4. Strategic initiatives
    • 12.4.14. Pharmexon
      • 12.4.14.1. Company overview
      • 12.4.14.2. Financial performance
      • 12.4.14.3. Product benchmarking
      • 12.4.14.4. Strategic initiatives
    • 12.4.15. Qvigilance
      • 12.4.15.1. Company overview
      • 12.4.15.2. Financial performance
      • 12.4.15.3. Product benchmarking
      • 12.4.15.4. Strategic initiatives
    • 12.4.16. BlueReg
      • 12.4.16.1. Company overview
      • 12.4.16.2. Financial performance
      • 12.4.16.3. Product benchmarking
      • 12.4.16.4. Strategic initiatives
    • 12.4.17. Cambridge Regulatory Services
      • 12.4.17.1. Company overview
      • 12.4.17.2. Financial performance
      • 12.4.17.3. Product benchmarking
      • 12.4.17.4. Strategic initiatives
    • 12.4.18. VCLS
      • 12.4.18.1. Company overview
      • 12.4.18.2. Financial performance
      • 12.4.18.3. Product benchmarking
      • 12.4.18.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 4 Global Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 5 Global Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 6 Global Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 7 Global Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 8 Global Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 9 Global Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 10 Global Regulatory Affairs, by Region, 2018 - 2030 (USD Billion)
  • Table 11 North America Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 12 North America Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 13 North America Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 14 North America Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 15 North America Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 16 North America Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 17 North America Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 18 U.S. Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 19 U.S. Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 20 U.S. Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 21 U.S. Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 22 U.S. Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 23 U.S. Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 24 U.S. Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 25 Canada Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 26 Canada Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 27 Canada Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 28 Canada Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 29 Canada Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 30 Canada Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 31 Canada Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 32 Europe Regulatory Affairs, by Country, 2018 - 2030 (USD Billion)
  • Table 33 Europe Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 34 Europe Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 35 Europe Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 36 Europe Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 37 Europe Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 38 Europe Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 39 Europe Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 40 Germany Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 41 Germany Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 42 Germany Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 43 Germany Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 44 Germany Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 45 Germany Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 46 Germany Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 47 UK Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 48 UK Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 49 UK Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 50 UK Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 51 UK Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 52 UK Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 53 UK Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 54 France Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 55 France Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 56 France Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 57 France Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 58 France Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 59 France Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 60 France Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 61 Italy Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 62 Italy Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 63 Italy Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 64 Italy Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 65 Italy Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 66 Italy Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 67 Italy Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 68 Spain Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 69 Spain Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 70 Spain Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 71 Spain Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 72 Spain Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 73 Spain Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 74 Spain Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 75 Denmark Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 76 Denmark Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 77 Denmark Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 78 Denmark Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 79 Denmark Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 80 Denmark Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 81 Denmark Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 82 Norway Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 83 Norway Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 84 Norway Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 85 Norway Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 86 Norway Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 87 Norway Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 88 Norway Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 89 Netherlands Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 90 Netherlands Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 91 Netherlands Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 92 Netherlands Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 93 Netherlands Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 94 Netherlands Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 95 Netherlands Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 96 Switzerland Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 97 Switzerland Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 98 Switzerland Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 99 Switzerland Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 100 Switzerland Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 101 Switzerland Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 102 Switzerland Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 103 Sweden Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 104 Sweden Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 105 Sweden Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 106 Sweden Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 107 Sweden Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 108 Sweden Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 109 Sweden Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 110 Asia Pacific Regulatory Affairs, by Country, 2018 - 2030 (USD Billion)
  • Table 111 Asia Pacific Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 112 Asia Pacific Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 113 Asia Pacific Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 114 Asia Pacific Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 115 Asia Pacific Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 116 Asia Pacific Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 117 Asia Pacific Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 118 China Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 119 China Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 120 China Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 121 China Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 122 China Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 123 China Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 124 China Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 125 Japan Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 126 Japan Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 127 Japan Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 128 Japan Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 129 Japan Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 130 Japan Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 131 Japan Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 132 India Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 133 India Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 134 India Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 135 India Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 136 India Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 137 India Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 138 India Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 139 South Korea Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 140 South Korea Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 141 South Korea Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 142 South Korea Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 143 South Korea Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 144 South Korea Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 145 South Korea Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 146 Australia Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 147 Australia Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 148 Australia Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 149 Australia Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 150 Australia Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 151 Australia Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 152 Australia Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 153 Thailand Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 154 Thailand Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 155 Thailand Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 156 Thailand Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 157 Thailand Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 158 Thailand Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 159 Thailand Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 160 Indonesia Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 161 Indonesia Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 162 Indonesia Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 163 Indonesia Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 164 Indonesia Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 165 Indonesia Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 166 Indonesia Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 167 Malaysia Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 168 Malaysia Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 169 Malaysia Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 170 Malaysia Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 171 Malaysia Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 172 Malaysia Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 173 Malaysia Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 174 Singapore Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 175 Singapore Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 176 Singapore Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 177 Singapore Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 178 Singapore Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 179 Singapore Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 180 Singapore Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 181 Taiwan Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 182 Taiwan Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 183 Taiwan Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 184 Taiwan Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 185 Taiwan Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 186 Taiwan Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 187 Taiwan Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 188 Latin America Regulatory Affairs, by Country, 2018 - 2030 (USD Billion)
  • Table 189 Latin America Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 190 Latin America Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 191 Latin America Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 192 Latin America Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 193 Latin America Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 194 Latin America Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 195 Latin America Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 196 Brazil Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 197 Brazil Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 198 Brazil Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 199 Brazil Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 200 Brazil Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 201 Brazil Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 202 Brazil Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 203 Mexico Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 204 Mexico Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 205 Mexico Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 206 Mexico Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 207 Mexico Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 208 Mexico Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 209 Mexico Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 210 Argentina Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 211 Argentina Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 212 Argentina Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 213 Argentina Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 214 Argentina Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 215 Argentina Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 216 Argentina Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 217 Colombia Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 218 Colombia Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 219 Colombia Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 220 Colombia Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 221 Colombia Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 222 Colombia Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 223 Colombia Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 224 Chile Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 225 Chile Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 226 Chile Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 227 Chile Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 228 Chile Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 229 Chile Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 230 Chile Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 231 Middle East & Africa Regulatory Affairs, by Country, 2018 - 2030 (USD Billion)
  • Table 232 Middle East & Africa Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 233 Middle East & Africa Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 234 Middle East & Africa Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 235 Middle East & Africa Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 236 Middle East & Africa Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 237 Middle East & Africa Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 238 Middle East & Africa Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 239 South Africa Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 240 South Africa Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 241 South Africa Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 242 South Africa Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 243 South Africa Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 244 South Africa Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 245 South Africa Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 246 Saudi Arabia Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 247 Saudi Arabia Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 248 Saudi Arabia Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 249 Saudi Arabia Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 250 Saudi Arabia Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 251 Saudi Arabia Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 252 Saudi Arabia Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 253 UAE Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 254 UAE Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 255 UAE Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 256 UAE Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 257 UAE Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 258 UAE Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 259 UAE Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 260 Egypt Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 261 Egypt Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 262 Egypt Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 263 Egypt Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 264 Egypt Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 265 Egypt Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 266 Egypt Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)
  • Table 267 Israel Regulatory Affairs, by Services, 2018 - 2030 (USD Billion)
  • Table 268 Israel Regulatory Affairs, by Category, 2018 - 2030 (USD Billion)
  • Table 269 Israel Regulatory Affairs, by Indication, 2018 - 2030 (USD Billion)
  • Table 270 Israel Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Billion)
  • Table 271 Israel Regulatory Affairs, by Type, 2018 - 2030 (USD Billion)
  • Table 272 Israel Regulatory Affairs, by Company Size, 2018 - 2030 (USD Billion)
  • Table 273 Israel Regulatory Affairs, by End Use, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Regulatory Affairs Market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot 1
  • Fig. 14 Segment snapshot 2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Regulatory Affairs Market: Services outlook key takeaways
  • Fig. 20 Regulatory Affairs Market: Services movement analysis
  • Fig. 21 Regulatory consulting market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 22 Legal representation market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 23 Regulatory writing & publishing market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 24 Writing market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 25 Publishing market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 26 Product registration & clinical trial applications market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 27 Other services market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 28 Regulatory Affairs Market: Category outlook key takeaways
  • Fig. 29 Regulatory Affairs Market: Category movement analysis
  • Fig. 30 Drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 31 Innovator drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 32 Preclinical innovator drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 33 Clinical innovator drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 34 Pre-Market Approval (PMA) innovator drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 35 Generic drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 36 Preclinical generic drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 37 Clinical generic drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 38 Pre-Market Approval (PMA) generic drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 39 Biologics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 40 Biotech market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 41 Preclinical biotech market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 42 Clinical biotech market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 43 Pre-Market Approval (PMA) biotech market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 44 ATMP market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 45 Preclinical ATMP market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 46 Clinical ATMP market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 47 Pre-Market Approval (PMA) ATMP market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 48 Biosimilars market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 49 Preclinical biosimilars market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 50 Clinical biosimilars market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 51 Pre-Market Approval (PMA) biosimilars market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 52 Medical Devices market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 53 Diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 54 Preclinical diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 55 Clinical diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 56 Pre-Market Approval (PMA) diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 57 Therapeutics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 58 Preclinical therapeutics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 59 Clinical therapeutics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 60 Pre-Market Approval (PMA) therapeutics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 61 Regulatory Affairs Market: Indication outlook key takeaways
  • Fig. 62 Regulatory Affairs Market: Indication movement analysis
  • Fig. 63 Oncology market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 64 Neurology market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 65 Cardiology companies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 66 Immunology market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 67 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 68 Regulatory Affairs Market: Product stage outlook key takeaways
  • Fig. 69 Regulatory Affairs Market: Product stage movement analysis
  • Fig. 70 Preclinical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 71 Clinical studies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 72 PMA companies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 73 Immunology market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 74 Regulatory Affairs Market: Type outlook key takeaways
  • Fig. 75 Regulatory Affairs Market: Type movement analysis
  • Fig. 76 In-house market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 77 Outsourced market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 78 Regulatory Affairs Market: Company size outlook key takeaways
  • Fig. 79 Regulatory Affairs Market: Company size movement analysis
  • Fig. 80 Small market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 81 Medium market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 82 Large market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 83 Regulatory Affairs Market: End Use outlook key takeaways
  • Fig. 84 Regulatory Affairs Market: End Use movement analysis
  • Fig. 85 Medical device companies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 86 Pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 87 Biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 88 Regional marketplace outlook, 2023 & 2030 (USD Billion)
  • Fig. 89 Regional marketplace: Key takeaways
  • Fig. 90 North America Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 91 Key country dynamics
  • Fig. 92 U.S. Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 93 Key country dynamics
  • Fig. 94 Canada Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 95 Key country dynamics
  • Fig. 96 Europe Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 97 Key country dynamics
  • Fig. 98 UK regulatory affairs market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 99 Key country dynamics
  • Fig. 100 Germany Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 101 Key country dynamics
  • Fig. 102 France Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 103 Key country dynamics
  • Fig. 104 Spain Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 105 Key country dynamics
  • Fig. 106 Italy Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 107 Key country dynamics
  • Fig. 108 Denmark Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 109 Key country dynamics
  • Fig. 110 Norway Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 111 Key country dynamics
  • Fig. 112 Netherlands Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 113 Key country dynamics
  • Fig. 114 Switzerland Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 115 Key country dynamics
  • Fig. 116 Sweden Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 117 Asia Pacific Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 118 Key country dynamics
  • Fig. 119 Japan Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 120 Key country dynamics
  • Fig. 121 China Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 122 Key country dynamics
  • Fig. 123 India Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 124 Key country dynamics
  • Fig. 125 Australia Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 126 Key country dynamics
  • Fig. 127 South Korea Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 128 Key country dynamics
  • Fig. 129 Thailand Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 130 Latin America Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 131 Key country dynamics
  • Fig. 132 Brazil Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 133 Key country dynamics
  • Fig. 134 Mexico Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 135 Key country dynamics
  • Fig. 136 Argentina Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 137 Key country dynamics
  • Fig. 138 Colombia regulatory affairs market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 139 Key country dynamics
  • Fig. 140 Chile regulatory affairs market estimates and forecasts, 2018 - 2030 (USD Billion) Key country dynamics
  • Fig. 141 MEA Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 142 Key country dynamics
  • Fig. 143 South Africa Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 144 Key country dynamics
  • Fig. 145 Saudi Arabia Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 146 Key country dynamics
  • Fig. 147 UAE Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 148 Key country dynamics
  • Fig. 149 Egypt regulatory affairs market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 150 Key country dynamics
  • Fig. 151 Israel regulatory affairs market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 152 Market participant categorization
  • Fig. 153 Regulatory affairs market position analysis, 2023
  • Fig. 154 Strategic framework